Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Ryght Introduces Ryght Preview, Enhancing Clinical Research and Operations for Sites, Sponsors, and CROs


Ryght's GenAI technology will optimize workflows, boost operational efficiency, and unlock new potential for the healthcare and life sciences industries

LAGUNA BEACH, Calif., April 16, 2024 /PRNewswire/ -- Ryght, a leading enterprise generative AI (GenAI) technology company for healthcare and life sciences, today announced the public availability of Ryght Preview. This offering invites knowledge workers to experience a seamless introduction to secure, industry-specific, enterprise-level GenAI technology. Ryght Preview comes pre-equipped with an expanding library of tailored "copilots," each designed to enhance daily productivity by streamlining routine tasks, with additional features accessible in the full enterprise version of Ryght.

Ryght's overarching goal is to streamline the interactions among research sites, Clinical Research Organizations (CROs), and clinical trial sponsors. By granting access to its platform, Ryght facilitates smoother operations and communication across these critical entities. Utilizing a wealth of clinical data and an ever-growing array of copilots, Ryght enhances clinical operations efficiency, delivering actionable insights and informed decision-making. This advancement can potentially accelerate the drug-to-market process, improve the success rates of clinical trials, and refine patient matching, thereby resolving the bottleneck between sponsors and trial sites.

"Ryght is a secure and user-friendly platform designed to meet the diverse needs of life science professionals looking to accelerate drug development by optimizing workflows, generating complex documents, or interrogating large amounts of unstructured data for optimal insights. Our platform will eliminate the need for these companies to allocate time and resources to internal teams to develop this technology themselves," said Simon Arkell, CEO and co-founder of Ryght. "Customized copilots can be added to the platform to reduce friction and optimize operations across all aspects of the clinical research continuum and beyond - whether that's by interrogating huge data lakes or writing protocols, informed consent documents or long proposals. Through the application of Ryght, we aim to further support our life science partners to boost operational efficiency and unlock a better future for the healthcare and life sciences industry."

Ryght Preview is available to life sciences knowledge workers as a free, secure platform with frictionless sign up. Ryght's copilot library consists of a diverse collection of tools to accelerate information retrieval, synthesis, and structuring of vast amounts of complex and unstructured data, and document builders, taking what might have taken weeks to complete down to days or hours. To inquire about custom building, collaborations, and access to additional copilots, contact Ryght's team of AI experts to discuss Ryght for Enterprise.  To attend today's LinkedIn Live with Tom Pike and Simon Arkell, Ryght co-founder and CEO, RSVP here.

About Ryght:
Ryght, an Nvidia Inception member, is a privately held healthcare technology company based in Laguna Beach, California developing the next generation of safe and secure generative artificial intelligence (GenAI) solutions for Healthcare and Life Sciences. The Ryght platform leverages multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to Life Sciences professionals.  The platform enables customers to rapidly leverage the power of GenAI within compliance of data security standards required by the industry. For more information, visit www.ryght.ai and follow the company on LinkedIn.

Company Contact
Brian Dranka, PhD
VP, Product & Marketing
[email protected]

SOURCE Ryght


These press releases may also interest you

at 01:30
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the...

at 01:00
Management Report1 Q1 2024 highlights Strong performance in Perfumery & Beauty on good demand developmentGood performance in Taste, Texture & Health underpinned by market recoveryHealth, Nutrition & Care was soft, with improving momentum by end of...

at 00:01
Today, the Conference on Jewish Material Claims Against Germany (Claims Conference) launched a new digital campaign, #CancelHate. The campaign features Holocaust survivors reading Holocaust denial posts from across social media platforms. Each post...

at 00:00
With over four decades of nursing experience under her belt, Sherry Shaffer Ratajczak has witnessed firsthand the dedication of her colleagues in patient care. Yet, she observed a common misunderstanding: many are unaware of the extensive knowledge...

1 mai 2024
Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto's favor on multiple grounds. This decision reverses the initial verdict of $185 million in its entirety and...

1 mai 2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc.  today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a...



News published on and distributed by: